Estrogen receptor alpha (ER-alpha) (ER-alpha)

The Estrogen receptor alpha (ER-alpha) within the osteoblastic pool is a key regulator of skeletal integrity and bone mass maintenance (UniProt P03372). Located in bone-forming osteoblasts, this receptor mediates the protective effects of estrogens by stimulating cell proliferation, differentiation, and the production of extracellular matrix components like Type I collagen (Almeida et al., 2017). ER-alpha signaling in osteoblasts also influences bone resorption indirectly by modulating the RANKL/Osteoprotegerin (OPG) ratio, which governs osteoclast activity (Manolagas, 2013). In postmenopausal states, the loss of estrogen leads to reduced signaling through this osteoblastic pool, triggering accelerated bone turnover and the development of osteoporosis (NIH Osteoporosis and Related Bone Diseases National Resource Center). Pharmacological agents such as Selective Estrogen Receptor Modulators (SERMs) are designed to target these receptors, acting as agonists in bone to prevent fractures while minimizing risks in other tissues (StatPearls: Selective Estrogen Receptor Modulators). Consequently, the osteoblastic ER pool remains a primary focus for therapeutic interventions aimed at treating metabolic bone disorders.

Other names

ESR1ER-alphaNuclear receptor subfamily 3 group A member 1Estrogen receptor 1Osteoblastic estrogen receptor pool

Selective estrogen receptor modulation (SERM) where the drug acts as an agonist in bone tissue to promote osteoblast activity and as an antagonist or neutral agent in breast and uterine tissues.